Skip to main content

Advertisement

SpringerLink
Log in

Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Compared with other breast cancer subtypes, triple negative breast cancers (TNBC) are associated with higher recurrence rates and worse survival. Because of the aggressive nature of TNBC, outcomes may be more sensitive to delays in time to treatment. This study evaluates whether delays from diagnosis to initial treatment in TNBC impacts survival or locoregional recurrence (LRR).

Methods

Retrospective review of TNBC patients treated between January 2004 and January 2011 at an academic center was performed. Data collected included demographics, pathology, treatment, recurrence, and survival. Interval to treatment was defined as days from pathologic diagnosis to first local or systemic treatment. The t test, Cox regression, and Kaplan–Meier analyses were used to evaluate impact of time to treatment on overall survival and LRR.

Results

Median follow-up was 40 months for 301 TNBC patients. Mean interval to treatment was 46 ± 2 days. Higher initial stage yielded worse survival (p < .0001). Interval to treatment did not impact overall survival (p = .24), although there was a trend toward worse survival with delays of >90 days (p = .06). LRR was seen in 20 patients (7 %). Median time to recurrence was 15 months. Time to treatment was 38 ± 6 days for patients with LRR versus 44 ± 2 days without a recurrence (p = .37). Short delay in time to treatment did not impact LRR (p = .54).

Conclusions

In TNBC, a short delay from pathologic diagnosis to initial treatment does not appear to adversely affect survival or LRR. Appropriate time to perform evaluations such as genetic testing, imaging, or additional consultation can be taken to guide optimal treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253:779–85.

    Article  PubMed  Google Scholar 

  2. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79:858–64.

    Article  PubMed  CAS  Google Scholar 

  3. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353:1119–26.

    Article  PubMed  CAS  Google Scholar 

  4. Fisher ER, Redmond C, Fisher B. A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer. 1977;40:3160–7.

    Article  PubMed  CAS  Google Scholar 

  5. Feldman JG, Saunders M, Carter AC, Gardner B. The effects of patient delay and symptoms other than a lump on survival in breast cancer. Cancer. 1983;51:1226–9.

    Article  PubMed  CAS  Google Scholar 

  6. Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet. 1999;353:1132–5.

    Article  PubMed  CAS  Google Scholar 

  7. Brazda A, Estroff J, Euhus D, Leitch AM, Huth J, Andrews V, et al. Delays in time to treatment and survival impact in breast cancer. Ann Surg Oncol. 2010;17 Suppl 3:291–6.

    Article  PubMed  Google Scholar 

  8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

  9. Finnegan TJ, Carey LA. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol. 2007;3:55–63.

    Article  PubMed  CAS  Google Scholar 

  10. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.

    Article  PubMed  CAS  Google Scholar 

  11. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21:50–7.

    Article  PubMed  Google Scholar 

  12. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15:303–8.

    Article  PubMed  Google Scholar 

  13. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.

    Article  PubMed  CAS  Google Scholar 

  14. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg. 2008;247:463–9.

    Article  PubMed  Google Scholar 

  15. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–82.

    Article  PubMed  Google Scholar 

  16. Lowery AJ, Kell MR, Glynn RW, Kerin MJ Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831–41.

    Article  PubMed  Google Scholar 

  17. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

    Article  PubMed  Google Scholar 

  18. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.

    Article  PubMed  Google Scholar 

  19. Fedewa SA, Edge SB, Stewart AK, Halpern MT, Marlow NM, Ward EM. Race and ethnicity are associated with delays in breast cancer treatment (2003–2006). J Health Care Poor Underserved. 2011;22:128–41.

    PubMed  Google Scholar 

  20. Kaufman CS, Landercasper J. Can we measure the quality of breast surgical care? Ann Surg Oncol. 2011;18:3053–60.

    Article  PubMed  Google Scholar 

  21. Malin JL, Schneider EC, Epstein AM, Adams J, Emanuel EJ, Kahn KL, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol. 2006;24:626–34.

    Article  PubMed  Google Scholar 

  22. Moran MS, Goss D, Haffty BG, Kaufman CS, Winchester DP. Quality measures, standards, and accreditation for breast centers in the United States. Int J Radiat Oncol Biol Phys. 2010;76:1–4.

    Article  PubMed  Google Scholar 

  23. Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99:488–90.

    Article  PubMed  Google Scholar 

  24. Kaufman CS, Shockney L, Rabinowitz B, Coleman C, Beard C, Landercasper J, et al. National Quality Measures for Breast Centers (NQMBC): a robust quality tool: breast center quality measures. Ann Surg Oncol. 2010;17:377–85.

    Article  PubMed  CAS  Google Scholar 

  25. Landercasper J, Linebarger JH, Ellis RL, Mathiason MA, Johnson JM, Marcou KA, et al. A quality review of the timeliness of breast cancer diagnosis and treatment in an integrated breast center. J Am Coll Surg. 2010;210:449–55.

    Article  PubMed  Google Scholar 

  26. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439–48.

    Article  PubMed  Google Scholar 

  27. Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012;23:324–31.

    Article  PubMed  CAS  Google Scholar 

  28. Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol. 2011;18:2858–65.

    Article  PubMed  Google Scholar 

  29. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29:2852–8.

    Article  PubMed  Google Scholar 

  30. Parker CC, Ampil F, Burton G, Li BD, Chu QD. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery. 2010;148:386–91.

    Article  PubMed  Google Scholar 

  31. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164–73.

    Article  PubMed  Google Scholar 

  32. IOM committee calls for complete revamping of health care system to achieve better quality. Qual Lett Healthc Lead. 2001;13:14–5.

    Google Scholar 

Download references

Acknowledgment

The authors wish to thank the David M. Crowley Foundation for their support of this research.

Disclosures

No financial disclosures.

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Amy Eastman MD, Yolanda Tammaro MD, Amy Moldrem MD, Valerie Andrews MD, James Huth MD, David Euhus MD, Marilyn Leitch MD & Roshni Rao MD

Authors
  1. Amy Eastman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yolanda Tammaro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy Moldrem MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valerie Andrews MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James Huth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Euhus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marilyn Leitch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roshni Rao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roshni Rao MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eastman, A., Tammaro, Y., Moldrem, A. et al. Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer. Ann Surg Oncol 20, 1880–1885 (2013). https://doi.org/10.1245/s10434-012-2835-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2835-z

Keywords

Search

Navigation